TennCare CMO launches programs aimed at improving health of Tennessee's Medicaid recipients.
U.S. Rep. Jim Cooper (TN-05), joined by U.S. Rep. Evan Jenkins (WV-03), U.S. Rep. Ann McLane Kuster (NH-02) and U.S. Rep. Tim Ryan (OH-13), today introduced bipartisan legislation repealing the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.
The Rainbow Program at Meharry offers pregnant and postpartum women with substance abuse disorders new hope.
From businessmen to housewives, today's opioid addicts are in a fight for their lives.
When asked how I manage wearing the different hats of pediatrician and president of the Tennessee Medical Association, the state's largest professional organization for doctors, my answer is always the same. It's all about the patients.
In a highly unusual move, the U.S. Food and Drug Administration has requested Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. In a release on June 8, the agency said it is seeking removal based on concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.
Calling it a 'Christmas miracle,' U.S. Sen. Lamar Alexander discusses the importance of the 21st Century Cures Act.
An increasing number of newborns are being born with drug withdrawal symptoms from opioids in rural areas of the United States as compared to births in urban areas, according to a JAMA Pediatrics study.
You may not be getting all you can out of your browsing experience
and may be open to security risks!
Consider upgrading to the latest version of your browser or choose on below: